Janumet 50/500 mg 56 tablets

Tradename

Janumet

Janumet

Composition

Each tablet contains:

Sitaglipin 50 mg

Metformin hydrochloride 500 mg

Auxiliary components:

microcrystalline cellulose, polyvinylpyrrolidone (povidone), sodium stearyl fumarate, sodium lauryl sulfate, purified water.

Properties

The drug is a combination of two hypoglycemic drugs with a complementary mechanism of action, designed to improve glycemic control in patients with type 2 diabetes mellitus: sitagliptin, an inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), and metformin, a representative of the biguanide class.

Metformin

Metformin is a hypoglycemic drug that increases glucose tolerance in patients with type 2 diabetes mellitus by lowering basal postprandial blood glucose concentrations. Its pharmacological mechanisms of action differ from the mechanisms of action of oral hypoglycemic drugs of other classes.

Indications

As a starting therapy for patients with type 2 diabetes mellitus to improve glycemic control, if diet and exercise regimens do not allow adequate control; as an adjunct to diet and exercise regimen to improve glycemic control in patients with type 2 diabetes mellitus who did not achieve adequate control against the background of monotherapy with metformi sitagliptin, or after unsuccessful combined treatment with two drugs.

Combination therapy: For patients with type 2 diabetes mellitus to improve glycemic control in combination with sulfonylurea derivatives (triple combination: metformin + sitagliptin + sulfonylurea derivative), when diet and exercise regimen are combined with two of these three drugs (metformin, sitagliptin or derivatives sulfonylureas) do not lead to adequate glycemic control; in combination with thiazolidinediones (PPARY receptor agonists activated by the peroxisome proliferator), when diet and exercise regimen in combination with two of these three drugs (metformin, sitagliptin or thiazolidinedione) do not lead to adequate glycemic control; in combination with insulin, when diet and exercise regimen in combination with insulin do not lead to adequate glycemic control.

Method of administration and dosage:

Contraindications

Type 1 diabetes mellitus; kidney disease or decreased renal function (with serum creatinine concentrations> 1.5 mg / dl and> 1.4 mg / dl in men and women, respectively, or decreased CC (<60 ml / min), including due to cardiovascular collapse (shock), acute myocardial infarction or septicemia; acute conditions occurring with the risk of developing renal dysfunction, such as dehydration (with diarrhea, vomiting), fever, severe infectious diseases, hypoxia (shock, sepsis, renal infections, bronchopulmonary diseases) ; acute or chronic metabolic acidosis, including diabetic ketoacidosis (with or without coma); clinically pronounced manifestations of acute and chronic diseases that can lead to the development of tissue hypoxia (including heart or respiratory failure, acute myocardial infarction); extensive surgery and trauma, when insulin therapy is indicated; liver failure, impaired liver function; chronic alcoholism, acute alcohol poisoning; pregnancy, lactation period; lactic acidosis (including a history); application for at least 48 hours before and within 48 hours after carrying out radioisotope or X-ray studies with the introduction of an iodine-containing contrast agent; adherenc a hypocaloric diet (less than 1000 kcal / day); children and adolescents up to 18 years old;

hypersensitivity to sitagliptin, metformin or any of the components of the drug. and history); application for at least 48 hours before and within 48 hours after carrying out radioisotope or X-ray studies with the introduction of an iodine-containing contrast agent; adherence to a hypocaloric diet (less than 1000 kcal / day); children and adolescents up to 18 years old; hypersensitivity to sitagliptin, metformin or any of the components of the drug. and history); application for at least 48 hours before and within 48 hours after carrying out radioisotope or X-ray studies with the introduction of an iodine-containing contrast agent; adherence to a hypocaloric diet (less than 1000 kcal / day); children and adolescents up to 18 years old; hypersensitivity to sitagliptin, metformin or any of the components of the drug.

Precautions:

Side effects

-headache,

-dizziness;

-hypoglycemia;